.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Daiichi Sankyo
Argus Health
US Army
McKinsey
US Department of Justice
McKesson
Moodys
Johnson and Johnson
Deloitte

Generated: June 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,256,310

« Back to Dashboard

Which drugs does patent 7,256,310 protect, and when does it expire?


Patent 7,256,310 protects XOPENEX HFA and is included in one NDA.

This patent has twenty-seven patent family members in eighteen countries.

Summary for Patent: 7,256,310

Title:Levalbuterol salt
Abstract:Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.
Inventor(s): McGlynn; Paul (Marlborough, MA), Bakale; Roger (Shrewsbury, MA), Sturge; Craig (Falmouth, CA)
Assignee: Sepracor Inc. (Marlborough, MA)
Application Number:10/728,873
Patent Claim Types:
see list of patent claims
Composition; Formulation; Delivery; Device; Process; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Sunovion
XOPENEX HFA
levalbuterol tartrate
AEROSOL, METERED;INHALATION021730-001Mar 11, 2005RXYesYes7,256,310► SubscribeYY TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,256,310

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,765,153Levalbuterol salt► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,256,310

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2507572► Subscribe
Cyprus1111330► Subscribe
Germany60304900► Subscribe
Germany60336089► Subscribe
Denmark1572622► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Teva
US Army
Citi
Dow
Cipla
Mallinckrodt
Cantor Fitzgerald
Baxter
Novartis
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot